Welcome to our dedicated page for Bolt Biotherapeutics SEC filings (Ticker: BOLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can feel like deciphering another language. Bolt Biotherapeutics’ reports are packed with immunology terms, trial protocols, and detailed R&D accounting that easily top 200 pages. If you have ever asked, “How do I read Bolt Biotherapeutics’ 10-K?” or searched for “Bolt Biotherapeutics SEC filings explained simply,” this page answers those questions in one place.
Stock Titan’s AI scans every disclosure the moment it hits EDGAR, then delivers plain-English summaries so you can grasp pipeline updates, cash runway, and partnership revenue without wading through biotech jargon. Whether you need the full “Bolt Biotherapeutics annual report 10-K simplified” or a quick look at “Bolt Biotherapeutics quarterly earnings report 10-Q filing,” our platform keeps you current.
Here’s how investors use the service:
- Track Bolt Biotherapeutics insider trading Form 4 transactions and receive Bolt Biotherapeutics Form 4 insider transactions real-time alerts.
- Review 8-K updates on trial data or partnerships with “Bolt Biotherapeutics 8-K material events explained.”
- Compare R&D spend trends with “Bolt Biotherapeutics earnings report filing analysis.”
- Dive into governance details via the “Bolt Biotherapeutics proxy statement executive compensation.”
Every filing type—10-K, 10-Q, 8-K, S-3, and more—arrives within seconds of posting, paired with expert context. Want help understanding Bolt Biotherapeutics SEC documents with AI? Our concise highlights show which Boltbody ISAC programs advanced phases, how much cash remains for clinical trials, and where executives are allocating equity through Bolt Biotherapeutics executive stock transactions Form 4. Stop sifting through dense biotech disclosures; let Stock Titan surface what matters, when it matters.
Form 4 overview: Director Laura Berner of Bolt Biotherapeutics (BOLT) reported a single equity-based transaction dated May 27 2025. She received a non-qualified stock option for 1,100 common shares at an exercise price of $6.40 per share. All figures give effect to the 1-for-20 reverse stock split that the company executed on June 6 2025.
Key terms of the grant:
- Vesting: Options vest on the earlier of May 27 2026 or the day immediately prior to the next annual meeting, subject to continued service.
- Change-in-control: The award vests in full upon a change-in-control event.
- Expiration: May 26 2035 (10-year life).
No shares were purchased or sold; the filing reflects compensation-related option issuance. Post-grant, Berner beneficially owns 1,100 derivative securities and no disclosed non-derivative common shares.
Corporate context: The recent reverse split consolidated each 20 common shares into one, reducing the share count and proportionally increasing exercise prices. Prior to the split, the grant was for 22,000 shares at $0.32 per share. The filing provides no additional financial or operational data.
Form 4 overview: Director Laura Berner of Bolt Biotherapeutics (BOLT) reported a single equity-based transaction dated May 27 2025. She received a non-qualified stock option for 1,100 common shares at an exercise price of $6.40 per share. All figures give effect to the 1-for-20 reverse stock split that the company executed on June 6 2025.
Key terms of the grant:
- Vesting: Options vest on the earlier of May 27 2026 or the day immediately prior to the next annual meeting, subject to continued service.
- Change-in-control: The award vests in full upon a change-in-control event.
- Expiration: May 26 2035 (10-year life).
No shares were purchased or sold; the filing reflects compensation-related option issuance. Post-grant, Berner beneficially owns 1,100 derivative securities and no disclosed non-derivative common shares.
Corporate context: The recent reverse split consolidated each 20 common shares into one, reducing the share count and proportionally increasing exercise prices. Prior to the split, the grant was for 22,000 shares at $0.32 per share. The filing provides no additional financial or operational data.
Form 4 overview: Director Laura Berner of Bolt Biotherapeutics (BOLT) reported a single equity-based transaction dated May 27 2025. She received a non-qualified stock option for 1,100 common shares at an exercise price of $6.40 per share. All figures give effect to the 1-for-20 reverse stock split that the company executed on June 6 2025.
Key terms of the grant:
- Vesting: Options vest on the earlier of May 27 2026 or the day immediately prior to the next annual meeting, subject to continued service.
- Change-in-control: The award vests in full upon a change-in-control event.
- Expiration: May 26 2035 (10-year life).
No shares were purchased or sold; the filing reflects compensation-related option issuance. Post-grant, Berner beneficially owns 1,100 derivative securities and no disclosed non-derivative common shares.
Corporate context: The recent reverse split consolidated each 20 common shares into one, reducing the share count and proportionally increasing exercise prices. Prior to the split, the grant was for 22,000 shares at $0.32 per share. The filing provides no additional financial or operational data.
AT&T Inc. (T) – Form 4 insider filing: Director Cindy B. Taylor reported an automatic, in-plan acquisition of 6,219.765 deferred stock units (DSUs) on 06/30/2025 under the company’s Non-Employee Director Stock and Deferral Plan. Each DSU represents the economic value of one common share and is settled in cash after the director leaves the board. The reference price recorded for the underlying common stock was $28.94.
Following the transaction, Taylor’s direct equity holdings remain at 5,718 common shares and 320 Series C depositary shares, while her indirect derivative position increases to 196,964.0096 DSUs held through the benefit plan. No shares were sold or disposed of, and there were no option exercises or other derivative conversions disclosed.
The filing indicates continued alignment between the director and shareholder interests but does not represent a material change to AT&T’s overall share structure or insiders’ cumulative ownership.
AT&T Inc. (T) – Form 4 insider filing: Director Cindy B. Taylor reported an automatic, in-plan acquisition of 6,219.765 deferred stock units (DSUs) on 06/30/2025 under the company’s Non-Employee Director Stock and Deferral Plan. Each DSU represents the economic value of one common share and is settled in cash after the director leaves the board. The reference price recorded for the underlying common stock was $28.94.
Following the transaction, Taylor’s direct equity holdings remain at 5,718 common shares and 320 Series C depositary shares, while her indirect derivative position increases to 196,964.0096 DSUs held through the benefit plan. No shares were sold or disposed of, and there were no option exercises or other derivative conversions disclosed.
The filing indicates continued alignment between the director and shareholder interests but does not represent a material change to AT&T’s overall share structure or insiders’ cumulative ownership.
FAQ
What is the current stock price of Bolt Biotherapeutics (BOLT)?
What is the market cap of Bolt Biotherapeutics (BOLT)?
What is the core focus of Bolt Biotherapeutics?
How does the Boltbody ISAC platform work?
What distinguishes Bolt Biotherapeutics’ approach from traditional therapies?
In which stage of development are its therapies currently?
What role does myeloid biology play in their technology?
How does Bolt Biotherapeutics position itself within the competitive biopharmaceutical market?
What are the key benefits of using tumor-targeting antibodies in their treatments?
Can you compare Bolt Biotherapeutics to other companies in the immuno-oncology space?
